TP53 and cancer: In the pretreated tumors, mutant p53 might exert cancer-promoting gain-of-function activities by disrupting the cytoplasmic DNA sensing machinery and the cGAS-STING pathway, leading to the suppression of the innate immune response through altered cytokine production19.